These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2355 related articles for article (PubMed ID: 25348937)

  • 1. Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer.
    Inoue T; Nishi T; Nakano Y; Nishimae A; Sawai Y; Yamasaki M; Inaji H
    Breast Cancer; 2016 Mar; 23(2):295-300. PubMed ID: 25348937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indocyanine green fluorescence mapping for sentinel lymph node biopsy in early breast cancer.
    Pitsinis V; Provenzano E; Kaklamanis L; Wishart GC; Benson JR
    Surg Oncol; 2015 Dec; 24(4):375-9. PubMed ID: 26555151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contrast-Enhanced Ultrasound Biopsy of Sentinel Lymph Nodes in Patients with Breast Cancer: Implications for Axillary Metastases and Conservation.
    Cox K; Weeks J; Mills P; Chalmers R; Devalia H; Fish D; Sever A
    Ann Surg Oncol; 2016 Jan; 23(1):58-64. PubMed ID: 25990967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the indocyanine green fluorescence and blue dye methods in detection of sentinel lymph nodes in early-stage breast cancer.
    Sugie T; Sawada T; Tagaya N; Kinoshita T; Yamagami K; Suwa H; Ikeda T; Yoshimura K; Niimi M; Shimizu A; Toi M
    Ann Surg Oncol; 2013 Jul; 20(7):2213-8. PubMed ID: 23429938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of completion axillary lymph node dissection in patients with immunohistochemical metastases to the sentinel lymph node in breast cancer.
    Pugliese MS; Karam AK; Hsu M; Stempel MM; Patil SM; Ho AY; Traina TA; Van Zee KJ; Cody HS; Morrow M; Gemignani ML
    Ann Surg Oncol; 2010 Apr; 17(4):1063-8. PubMed ID: 20033325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sentinel lymph node biopsy in breast cancer guided by indocyanine green fluorescence.
    Murawa D; Hirche C; Dresel S; Hünerbein M
    Br J Surg; 2009 Nov; 96(11):1289-94. PubMed ID: 19847873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ICG fluorescence-guided sentinel node biopsy for axillary nodal staging in breast cancer.
    Hirche C; Murawa D; Mohr Z; Kneif S; Hünerbein M
    Breast Cancer Res Treat; 2010 Jun; 121(2):373-8. PubMed ID: 20140704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer--results of the ALMANAC validation phase.
    Goyal A; Newcombe RG; Chhabra A; Mansel RE;
    Breast Cancer Res Treat; 2006 Sep; 99(2):203-8. PubMed ID: 16541308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of indocyanine green fluorescence imaging plus blue dye and blue dye alone for sentinel node navigation surgery in breast cancer patients.
    Hirano A; Kamimura M; Ogura K; Kim N; Hattori A; Setoguchi Y; Okubo F; Inoue H; Miyamoto R; Kinoshita J; Fujibayashi M; Shimizu T
    Ann Surg Oncol; 2012 Dec; 19(13):4112-6. PubMed ID: 22782671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting axillary sentinel node status in patients with primary breast cancer.
    Kolarik D; Pecha V; Skovajsova M; Zahumensky J; Trnkova M; Petruzelka L; Halaska M; Sottner O; Otcenasek M; Kolarova H
    Neoplasma; 2013; 60(3):334-42. PubMed ID: 23374005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term prognoses and outcomes of axillary lymph node recurrence in 2,578 sentinel lymph node-negative patients for whom axillary lymph node dissection was omitted: results from one Japanese hospital.
    Ogiya A; Kimura K; Nakashima E; Sakai T; Miyagi Y; Iijima K; Morizono H; Makita M; Horii R; Akiyama F; Iwase T
    Breast Cancer; 2016 Mar; 23(2):318-22. PubMed ID: 25376341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the indocyanine green dye method versus the combined method of indigo carmine blue dye with indocyanine green fluorescence imaging for sentinel lymph node biopsy in breast conservative therapy for stage ≤IIA breast cancer.
    Takemoto N; Koyanagi A; Yasuda M; Yamamoto H
    BMC Womens Health; 2018 Sep; 18(1):151. PubMed ID: 30227837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of the additional use of blue dye for indocyanine green for sentinel node biopsy in breast cancer.
    Ji Y; Luo N; Jiang Y; Li Q; Wei W; Yang H; Liu J
    J Surg Res; 2017 Jul; 215():88-92. PubMed ID: 28688667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Dutch Prediction Tool to Assess the Risk of Additional Axillary Non-Sentinel Lymph Node Involvement in Sentinel Node-Positive Breast Cancer Patients.
    van den Hoven I; van Klaveren D; Voogd AC; Vergouwe Y; Tjan-Heijnen V; Roumen RM
    Clin Breast Cancer; 2016 Apr; 16(2):123-30. PubMed ID: 26602438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the benefit of using blue dye in addition to indocyanine green fluorescence for sentinel lymph node biopsy in patients with breast cancer.
    Guo W; Zhang L; Ji J; Gao W; Liu J; Tong M
    World J Surg Oncol; 2014 Sep; 12():290. PubMed ID: 25239029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High rate of solitary sentinel node metastases identification by fluorescence-guided lymphatic imaging in breast cancer.
    Hirche C; Mohr Z; Kneif S; Murawa D; Hünerbein M
    J Surg Oncol; 2012 Feb; 105(2):162-6. PubMed ID: 21882198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of sentinel lymph node biopsy guided by the multimodal method of indocyanine green fluorescence, radioisotope, and blue dye versus the radioisotope method in breast cancer: a randomized controlled trial.
    Jung SY; Kim SK; Kim SW; Kwon Y; Lee ES; Kang HS; Ko KL; Shin KH; Lee KS; Park IH; Ro J; Jeong HJ; Joo J; Kang SH; Lee S
    Ann Surg Oncol; 2014 Apr; 21(4):1254-9. PubMed ID: 24356798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blue dye is sufficient for sentinel lymph node biopsy in breast cancer.
    Ang CH; Tan MY; Teo C; Seah DW; Chen JC; Chan MY; Tan EY
    Br J Surg; 2014 Mar; 101(4):383-9; discussion 389. PubMed ID: 24492989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of sentinel node biopsy by combined fluorescent and dye method and lymph flow for breast cancer.
    Hojo T; Nagao T; Kikuyama M; Akashi S; Kinoshita T
    Breast; 2010 Jun; 19(3):210-3. PubMed ID: 20153649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erratum to: Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up.
    Kiluk JV; Ly QP; Santillan AA; Meade T; Ramos D; Reintgen DS; Dessureault S; Davis M; Shamehdi C; Cox CE
    Ann Surg Oncol; 2010 Feb; 17(2):552-7. PubMed ID: 19957043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 118.